NCT01989585 2026-03-18Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant MelanomaNational Cancer Institute (NCI)Phase 1/2 Active not recruiting75 enrolled